<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02292823</url>
  </required_header>
  <id_info>
    <org_study_id>IMD-13</org_study_id>
    <nct_id>NCT02292823</nct_id>
  </id_info>
  <brief_title>MGuard™ Prime Embolic Protection Stent in Patients With Acute ST Elevation Myocardial Infarction</brief_title>
  <acronym>e-MASTER</acronym>
  <official_title>e-MASTER Registry: MGuard™ Prime Embolic Protection Stent in Patients With Acute ST Elevation Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InspireMD</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InspireMD</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, non-randomized, single arm, multicenter observational study. The objective is to
      evaluate the safety and efficacy of the MGuard™ Prime stent in the treatment of de novo
      stenotic lesions in coronary arteries in patients undergoing primary percutaneous coronary
      intervention (PCI) due to acute ST elevation myocardial infarction (STEMI) in a real-world
      setting.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Enrolment rate
  </why_stopped>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Complete ST-segment resolution</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>All cause death or MI at 30 days</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>TIMI flow grade</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac Events rate (MACE): cardiac death, re-MI, clinically-driven target lesion revascularization (TLR)</measure>
    <time_frame>Discharge, 30 days, 6 months, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute success rates</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis rate</measure>
    <time_frame>Discharge, 30 days, 6 months,12 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">63</enrollment>
  <condition>ST Elevation Myocardial Infarction</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MGuard™ Prime Embolic Protection Stent System</intervention_name>
    <other_name>MGuard™ Prime EPS</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects undergoing primary revascularization for STEMI and who are intended to undergo
        primary PCI with the MGuard™ Prime Embolic Protection Stent System.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is &gt;18 years of age.

          2. Subject is experiencing clinical symptoms consistent with ST elevation acute
             myocardial infarction (STEMI) of &gt;30 minutes and &lt;24 hours.

          3. Based on coronary anatomy, primary PCI is indicated for the culprit lesion with
             anticipated use of stenting.

          4. Subject agrees to all required follow-up procedures and visits and has provided
             informed consent where required.

          5. The target lesion is a de novo lesion in a native coronary artery.

          6. The reference vessel diameter (RVD) of the infarct lesion is 2.75-4.0 mm by visual
             assessment.

        Exclusion Criteria:

          1. Subject undergoing cardiopulmonary resuscitation.

          2. Cardiogenic shock (SBP &lt;80 mmHg for &gt;30 minutes, or requiring IV pressors or
             intra-aortic balloon bump (IABP) or other hemodynamic support device for hypotension).

          3. Co-morbid condition(s) or others that could limit the subject's ability to participate
             in the trial or to comply with follow-up requirements, or impact the scientific
             integrity of the trial.

          4. Target lesion involves a bifurcation with a side branch &gt;/=2.0 mm in diameter.

          5. In the Investigator's opinion the lesion/vessel is unsuitable for treatment with the
             MGuard™ Prime Embolic Protection Stent System for any reason.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Onze Lieve Vrouwe Gasthuis</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2014</study_first_submitted>
  <study_first_submitted_qc>November 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2014</study_first_posted>
  <last_update_submitted>August 31, 2015</last_update_submitted>
  <last_update_submitted_qc>August 31, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>STEMI</keyword>
  <keyword>heart attack</keyword>
  <keyword>stent</keyword>
  <keyword>Bare Metal Stent</keyword>
  <keyword>myocardial infarction</keyword>
  <keyword>PCI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

